# iBio, Inc.: overview IBIO · Nasdaq · CIK 1420720 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30 Pages: [Overview](/companies/ibio.md) · [Financials](/companies/ibio/financials.md) · [Filings](/companies/ibio/filings.md) · [Insiders](/companies/ibio/insiders.md) Latest reported revenue: [$0](/filings/0001420720-26-000020.md) for Q4 FY2026, three months to 2026-06-30, from the 10-K filed Aug 28, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001420720-26-000020). ## Last eight quarters | Line item | Unit | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [0.0](/filings/0001420720-25-000043.md) | [200](/filings/0001420720-26-000004.md) | [0.0](/filings/0001420720-25-000025.md) | [200 d](/filings/0001420720-26-000020.md) | [100](/filings/0001420720-25-000043.md) | [0.0](/filings/0001420720-26-000004.md) | [0.0 d](/filings/0001104659-26-059416.md) | [0.0 d](/filings/0001420720-26-000020.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | [(2209.5%)](/filings/0001420720-26-000004.md) | not reported | [(2599.0%) d](/filings/0001420720-26-000020.md) | [(5951.0%)](/filings/0001420720-25-000043.md) | not reported | not reported | not reported | | Net margin | % | not reported | [(2182.0%)](/filings/0001104659-26-059416.md) | not reported | [(2581.5%) d](/filings/0001420720-26-000020.md) | [(5720.0%)](/filings/0001104659-26-059416.md) | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.46)](/filings/0001420720-25-000043.md) | [(0.48)](/filings/0001420720-26-000004.md) | [(0.49)](/filings/0001104659-26-059416.md) | not reported | [(0.11)](/filings/0001420720-25-000043.md) | [(0.09)](/filings/0001420720-26-000004.md) | [(0.06)](/filings/0001104659-26-059416.md) | not reported | | Free cash flow | $k | [(3,715)](/filings/0001420720-25-000043.md) | [(3,870) d](/filings/0001420720-26-000004.md) | [(3,119) d](/filings/0001104659-26-059416.md) | [(4,616) d](/filings/0001420720-26-000020.md) | [(5,697)](/filings/0001420720-25-000043.md) | [(5,757) d](/filings/0001420720-26-000004.md) | [(6,095) d](/filings/0001104659-26-059416.md) | [(6,247) d](/filings/0001420720-26-000020.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 9-month figure less the 6-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 9-month figure less the 6-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 9-month figure less the 6-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 9-month figure less the 6-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-06-30) | FY2023 (2023-06-30) | FY2024 (2024-06-30) | FY2025 (2025-06-30) | FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1.9](/filings/0001420720-23-000045.md) | [0.0](/filings/0001420720-24-000041.md) | [0.2](/filings/0001558370-25-011888.md) | [0.4](/filings/0001420720-26-000020.md) | [0.1](/filings/0001420720-26-000020.md) | | Gross margin | % | [115.0%](/filings/0001420720-22-000064.md) | not reported | not reported | not reported | not reported | | Operating margin | % | [(1576.3%)](/filings/0001420720-23-000045.md) | not reported | [(7392.9%)](/filings/0001558370-25-011888.md) | [(4650.5%)](/filings/0001420720-26-000020.md) | [(35141.0%)](/filings/0001420720-26-000020.md) | | Net margin | % | [(2670.0%)](/filings/0001420720-22-000064.md) | not reported | [(11069.8%)](/filings/0001558370-25-011888.md) | [(4594.3%)](/filings/0001420720-26-000020.md) | [(33044.0%)](/filings/0001420720-26-000020.md) | | Diluted EPS | $ per share | [(5.78)](/filings/0001420720-23-000045.md) | [(106.19)](/filings/0001420720-24-000041.md) | [(6.50)](/filings/0001558370-25-011888.md) | [(1.75)](/filings/0001420720-26-000020.md) | [(0.32)](/filings/0001420720-26-000020.md) | | Free cash flow | $m | [(44.8)](/filings/0001420720-23-000045.md) | [(36.2)](/filings/0001420720-24-000041.md) | [(18.8)](/filings/0001558370-25-011888.md) | [(15.3)](/filings/0001420720-26-000020.md) | [(23.8)](/filings/0001420720-26-000020.md) | - Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ibio/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Affinity Asset Advisors, LLC](/funds/1773195.md) | 2026-06-30 | $7.0m | 4,007,881 | | Added +900,681 | | [Cormorant Asset Management, LP](/funds/1583977.md) | 2026-06-30 | $6.2m | 3,570,000 | | New +3,570,000 | | [SILVERARC CAPITAL MANAGEMENT, LLC](/funds/1816307.md) | 2026-06-30 | $6.2m | 3,520,490 | | Added +3,294,490 | | [Vestal Point Capital, LP](/funds/1974915.md) | 2026-06-30 | $4.5m | 2,600,000 | | New +2,600,000 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $3.7m | 2,098,151 | | Added +1,009,852 | | [Frazier Life Sciences Management, L.P.](/funds/1892134.md) | 2026-06-30 | $3.4m | 1,953,467 | | Unchanged | | [Ensign Peak Advisors, Inc](/funds/1454984.md) | 2026-06-30 | $3.2m | 1,832,457 | | New +1,832,457 | | [Woodline Partners LP](/funds/1784547.md) | 2026-06-30 | $3.1m | 1,776,547 | | New +1,776,547 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $2.9m | 1,651,473 | | Added +101,623 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $2.4m | 1,384,029 | | Added +427,600 | ## Recent filings [All 882 filings](/companies/ibio/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-19 | 20:16 ET | [8-K](/filings/0001420720-26-000032.md) | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001420720-26-000032 | | 2026-10-13 | 12:25 ET | [8-K](/filings/0001420720-26-000030.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001420720-26-000030 | | 2026-09-14 | 20:16 ET | [8-K](/filings/0001420720-26-000028.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001420720-26-000028 | | 2026-09-04 | 20:05 ET | [DEF 14A](/filings/0001420720-26-000022.md) | Proxy statement, period 2026-09-04 | 0001420720-26-000022 | | 2026-08-28 | 12:32 ET | [10-K](/filings/0001420720-26-000020.md) | Annual report, period 2026-06-30 | 0001420720-26-000020 | | 2026-08-28 | 12:30 ET | [8-K](/filings/0001420720-26-000019.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001420720-26-000019 | | 2026-08-04 | 11:05 ET | [8-K](/filings/0001420720-26-000014.md) | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001420720-26-000014 | | 2026-07-17 | 20:08 ET | [8-K](/filings/0001420720-26-000012.md) | 5.08 Item not in the standard list; 8.01 Other events; 9.01 Financial statements and exhibits | 0001420720-26-000012 | | 2026-07-01 | 11:33 ET | [8-K](/filings/0001420720-26-000010.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001420720-26-000010 | | 2026-05-12 | 20:18 ET | [10-Q](/filings/0001104659-26-059416.md) | Quarterly report, period 2026-03-31 | 0001104659-26-059416 | ## Latest annual report [Form 10-K for the fiscal year ended Jun 30, 2026](/filings/0001420720-26-000020.md), filed Aug 28, 2026. ## Forecast league Q1 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/92f40041-6cbd-401c-a578-fcf62a2aa661) ## About the filer - CIK: 1420720 - Tickers: IBIO - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.